Paediatric Diseases Working Party (PDWP)
Type d'étude:
Numéro de l'étude:
8417018
Type de traitement à base de cellules souches:
Allogeneic
Maladies:
Acute Myeloid Leukaemia (AML)
Titre court:
Etude comparative MAC Séqentiels.
Objectif principal:
The primary end points are:
• 2 years overal survival OS)
• 2 years disease free survival (DFS)
Death from any cause will be considered as an event. Event will be summarized by a survival curve. Surviving patients will be censored at time of last follow-up.
Comparison of DFS and OS will be performed between patients who received a sequential conditioning and those who received a standard myeloablative conditioning regimen.
• 2 years overal survival OS)
• 2 years disease free survival (DFS)
Death from any cause will be considered as an event. Event will be summarized by a survival curve. Surviving patients will be censored at time of last follow-up.
Comparison of DFS and OS will be performed between patients who received a sequential conditioning and those who received a standard myeloablative conditioning regimen.
Principaux critères d'inclusion:
-Age at transplant below to 18 years.
-Acute myeloide leukemia (without secondary AML or MDS)
- First HSCT
-Refractory disease at transplant (> 5% of marrow blasts at transplant).
- Transplantation between 2000 et 2015
-Acute myeloide leukemia (without secondary AML or MDS)
- First HSCT
-Refractory disease at transplant (> 5% of marrow blasts at transplant).
- Transplantation between 2000 et 2015
Pays:
France
Investigateur principal:
Audrey Grain
Coordinateur EBMT de l'étude:
Arnaud Dalissier
E-mail du coordinateur de l'étude:
arnaud.dalissier@upmc.fr